New hope for brain cancer: experimental combo targets recurrent glioblastoma

NCT ID NCT06061809

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times

Summary

This study tests combinations of experimental drugs (nogapendekin alfa inbakicept, PD-L1 t-haNK, bevacizumab) and tumor treatment fields in people whose glioblastoma has returned or worsened. The goal is to see if these treatments are safe and can help control the cancer. About 34 adults with recurrent glioblastoma will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chan Soon-Shiong Institute for Medicine (CSSIFM)

    NOT_YET_RECRUITING

    El Segundo, California, 90245, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hoag Memorial Hospital Presbyterian

    RECRUITING

    Newport Beach, California, 92663, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact

  • Providence Medical Foundation

    RECRUITING

    Fullerton, California, 92835, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.